Increasing clinicians’ suspicion of ATTR amyloidosis using a retrospective algorithm

Oct 15, 2024

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Read more

Oct 08, 2024

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Read more

Aug 30, 2024

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Read more

Aug 07, 2024

Drug Development for Transthyretin Amyloidosis

Read more

Jun 24, 2024

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Read more

May 24, 2024

Impact of Semaglutide in Amyloid Positivity (ISAP)

Read more

Apr 15, 2024

Novo Nordisk gets grant for antibodies binding to human transthyretin for treating TTR amyloidosis

Read more

Jan 24, 2024

Transthyretin Amyloidosis Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Players - Attralus, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Novo Nordisk

Read more

Aug 27, 2023

Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CM

Read more

Apr 24, 2023

Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks

Read more

Subscribe to